The outcome of directional subthalamic deep brain stimulation in advanced Parkinson’s disease
Objective: To assess the outcome of patients with advanced Parkinson’s disease (PD) treated with directional DBS. Background: Subthalamic deep brain stimulation (STN-DBS) has proved to…Speech Intelligibility in Parkinson’s disease following Intensive Voice and Articulation Treatments
Objective: Our aim was to evaluate the impact of voice treatment (LSVT LOUD) and articulation treatment (LSVT ARTIC) on speech and consonant intelligibility in Parkinson's…Impact on the Quality of Life (CV) of people with Parkinson’s disease participating in community workshops of the public health system of Coquimbo, Chile
Objective: To show the Impact in the CV of the People with Parkinson's Disease through the permanent assistance to the multidisciplinary community workshops of their…A randomized double-blind placebo-controlled trial of probiotics for constipation in Parkinson’s disease
Objective: To investigate the effects of probiotics on constipation in PD, using a randomized controlled trial (RCT) design Background: Non-motor symptoms (NMS) cause significant disability…Five Year Outcomes of a Prospective, Multicenter Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s Disease
Objective: To evaluate the long term follow up of patients in the VANTAGE Study that employed a Deep Brain Stimulation (DBS) system with multiple independent…A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease
Objective: To develop a novel disease-modifying therapy in Parkinson's disease (PD) that affects both motor and non-motor symptoms, based on a novel stress-protective protein CDNF.…Bdnf rs6265 and Other Variants Predict the Efficacy of Levodopa Monotherapy in Early-Stage Parkinson’s Disease
Objective: To determine whether relatively prevalent variants in the gene for brain-derived neurotrophic factor (Bdnf) are associated with differential efficacy of levodopa or other dopaminergic…The Akt/mTOR/P70S6K/4EB-P1 signaling pathway is activated by metformin in a toxin-induced cellular model of Parkinson’s disease
Objective: To investigate the effects of metformin on the Akt/mTOR/P70S6K/4EB-P1 signaling pathway in a cellular model of Parkinson’s disease (PD). Background: Metformin is a drug…Highly-selective blockade of 5-HT2A receptors with EMD-281,014 reduces the severity of L-DOPA-induced psychosis and dyskinesia in the MPTP-lesioned marmoset model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A) receptor EMD-281,014 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone
Objective: ODM-104 is a novel non-nitrocatechol catechol-O-methyltransferase (COMT) inhibitor that is undergoing clinical evaluation for Parkinson’s disease (PD). This study investigated the pharmacodynamic effects of…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.